Larry Jones - Biostem Technologies Chief Officer
BSEM Stock | USD 15.00 0.49 3.16% |
Insider
Larry Jones is Chief Officer of Biostem Technologies
Phone | 954 380 8342 |
Web | https://www.biostemtechnologies.com |
Biostem Technologies Management Efficiency
The company has return on total asset (ROA) of (0.6018) % which means that it has lost $0.6018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2102) %, meaning that it created substantial loss on money invested by shareholders. Biostem Technologies' management efficiency ratios could be used to measure how well Biostem Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | INSIDER Age | ||
Wilfried Freudenberg | CSL Limited | N/A | |
Douglas Langa | Novo Nordisk AS | 57 | |
Christina Hickie | CSL | N/A | |
MS BA | CSL Limited | 53 | |
BS BS | CSL | 61 | |
Monique Carter | Novo Nordisk AS | 50 | |
Christina Hickie | CSL Limited | N/A | |
BS BS | CSL Limited | 61 | |
Marcus Schindler | Novo Nordisk AS | 57 | |
Wilfried Freudenberg | CSL | N/A | |
Martin Lange | Novo Nordisk AS | 55 | |
Lars Jorgensen | Novo Nordisk AS | 57 | |
Paul BA | CSL Limited | 66 | |
MS BA | CSL | 53 | |
Jemimah Brennan | CSL Limited | N/A | |
Ourania Tatsis | Vertex Pharmaceuticals | 53 | |
Jemimah Brennan | CSL | N/A | |
BCom BComm | CSL Limited | 57 | |
BCom BComm | CSL | 57 | |
Paul BA | CSL | 66 | |
Martin Lange | Novo Nordisk AS | 53 |
Management Performance
Return On Equity | -2.21 | |||
Return On Asset | -0.6 |
Biostem Technologies Leadership Team
Elected by the shareholders, the Biostem Technologies' board of directors comprises two types of representatives: Biostem Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biostem. The board's role is to monitor Biostem Technologies' management team and ensure that shareholders' interests are well served. Biostem Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biostem Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Irmgard MD, International Officer | ||
Jason Matuszewski, Chairman and President and Secretary | ||
Andrew VanVurst, COO Director | ||
Larry Jones, Chief Officer | ||
Michael CPA, Chief Officer | ||
David Woynarowski, Chief Officer |
Biostem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Biostem Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -2.21 | |||
Return On Asset | -0.6 | |||
Operating Margin | (18.22) % | |||
Current Valuation | 37.89 M | |||
Shares Outstanding | 9.24 M | |||
Price To Earning | (0.49) X | |||
Price To Sales | 151.81 X | |||
Revenue | 2.52 M | |||
Gross Profit | 163.78 K | |||
EBITDA | (1.59 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.